Terms: = Leukemia AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Treatment
150 results:
1. Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid leukemia.
Monteith AJ; Ramsey HE; Silver AJ; Brown D; Greenwood D; Smith BN; Wise AD; Liu J; Olmstead SD; Watke J; Arrate MP; Gorska AE; Fuller L; Locasale JW; Stubbs MC; Rathmell JC; Savona MR
Cancer Res; 2024 Apr; 84(7):1101-1114. PubMed ID: 38285895
[TBL] [Abstract] [Full Text] [Related]
2. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia.
El-Tanani M; Nsairat H; Matalka II; Lee YF; Rizzo M; Aljabali AA; Mishra V; Mishra Y; Hromić-Jahjefendić A; Tambuwala MM
Pathol Res Pract; 2024 Feb; 254():155161. PubMed ID: 38280275
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract] [Full Text] [Related]
4. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
[TBL] [Abstract] [Full Text] [Related]
5. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Birdwell CE; Fiskus W; Kadia TM; Mill CP; Sasaki K; Daver N; DiNardo CD; Pemmaraju N; Borthakur G; Davis JA; Das K; Sharma S; Horrigan S; Ruan X; Su X; Khoury JD; Kantarjian H; Bhalla KN
Leukemia; 2024 Mar; 38(3):545-556. PubMed ID: 38086946
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation.
Yu S; Zhang Y; Yang J; Xu H; Lan S; Zhao B; Luo M; Ma X; Zhang H; Wang S; Shen H; Zhang Y; Xu Y; Li R
Eur J Med Chem; 2024 Jan; 263():115924. PubMed ID: 37992518
[TBL] [Abstract] [Full Text] [Related]
7. Anti-inflammatory effects of cold atmospheric plasma irradiation on the THP-1 human acute monocytic leukemia cell line.
Hirasawa I; Odagiri H; Park G; Sanghavi R; Oshita T; Togi A; Yoshikawa K; Mizutani K; Takeuchi Y; Kobayashi H; Katagiri S; Iwata T; Aoki A
PLoS One; 2023; 18(10):e0292267. PubMed ID: 37851686
[TBL] [Abstract] [Full Text] [Related]
8. IκB kinase-α coordinates brd4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy.
Pecharromán I; Solé L; Álvarez-Villanueva D; Lobo-Jarne T; Alonso-Marañón J; Bertran J; Guillén Y; Montoto Á; Martínez-Iniesta M; García-Hernández V; Giménez G; Salazar R; Santos C; Garrido M; Borràs E; Sabidó E; Bonfill-Teixidor E; Iurlaro R; Seoane J; Villanueva A; Iglesias M; Bigas A; Espinosa L
EMBO J; 2023 Nov; 42(21):e114719. PubMed ID: 37737566
[TBL] [Abstract] [Full Text] [Related]
9. Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.
Liccardo F; Śniegocka M; Tito C; Iaiza A; Ottone T; Divona M; Travaglini S; Mattei M; Cicconi R; Miglietta S; Familiari G; Nottola SA; Petrozza V; Tamagnone L; Voso MT; Masciarelli S; Fazi F
J Exp Clin Cancer Res; 2023 Aug; 42(1):223. PubMed ID: 37653435
[TBL] [Abstract] [Full Text] [Related]
10. brd4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract] [Full Text] [Related]
11. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.
Senapati J; Fiskus WC; Daver N; Wilson NR; Ravandi F; Garcia-Manero G; Kadia T; DiNardo CD; Jabbour E; Burger J; Short NJ; Alvarado Y; Jain N; Masarova L; Issa GC; Qiao W; Khoury JD; Pierce S; Miller D; Sasaki K; Konopleva M; Bhalla KN; Borthakur G; Pemmaraju N
Clin Cancer Res; 2023 Nov; 29(21):4352-4360. PubMed ID: 37585491
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of the novel therapeutic anti-CCR7 antibody cap-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C
Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392
[TBL] [Abstract] [Full Text] [Related]
13. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R; Secker-Grob KA; Keppeler H; Korkmaz F; Schairer R; Erkner E; Schneidawind D; Lengerke C; Hentrich T; Schulze-Hentrich JM; Schneidawind C
Neoplasia; 2023 Jul; 41():100902. PubMed ID: 37148657
[TBL] [Abstract] [Full Text] [Related]
14. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN
Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414
[TBL] [Abstract] [Full Text] [Related]
15. Targeting Proliferation Signals and the Cell Cycle Machinery in Acute leukemias: Novel Molecules on the Horizon.
Ghelli Luserna di Rorà A; Jandoubi M; Martinelli G; Simonetti G
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770891
[TBL] [Abstract] [Full Text] [Related]
16. ACC010, a novel brd4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.
Qian Y; Zhang X; Mao S; Wei W; Lin X; Ling Q; Ye W; Li F; Pan J; Zhou Y; Zhao Y; Huang X; Huang J; Tong H; Sun J; Jin J
Mol Oncol; 2023 Jul; 17(7):1402-1418. PubMed ID: 36567628
[TBL] [Abstract] [Full Text] [Related]
17. Design, synthesis, and biological evaluation of brd4 degraders.
Ding M; Shao Y; Sun D; Meng S; Zang Y; Zhou Y; Li J; Lu W; Zhu S
Bioorg Med Chem; 2023 Jan; 78():117134. PubMed ID: 36563515
[TBL] [Abstract] [Full Text] [Related]
18. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Fooks K; Galicia-Vazquez G; Gife V; Schcolnik-Cabrera A; Nouhi Z; Poon WWL; Luo V; Rys RN; Aloyz R; Orthwein A; Johnson NA; Hulea L; Mercier FE
J Exp Clin Cancer Res; 2022 Dec; 41(1):340. PubMed ID: 36482393
[TBL] [Abstract] [Full Text] [Related]
19. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer.
Yan G; Luna A; Wang H; Bozorgui B; Li X; Sanchez M; Dereli Z; Kahraman N; Kara G; Chen X; Zheng C; McGrail D; Sahni N; Lu Y; Babur O; Cokol M; Lim B; Ozpolat B; Sander C; Mills GB; Korkut A
Cell Rep; 2022 Sep; 40(11):111304. PubMed ID: 36103824
[TBL] [Abstract] [Full Text] [Related]
20. brd4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract] [Full Text] [Related]
[Next]
